Volume 6, Issue 5, Pages (November 2002)

Slides:



Advertisements
Similar presentations
Volume 5, Issue 3, Pages (March 2002)
Advertisements

Cardiac-Specific Overexpression of HIF-1α Prevents Deterioration of Glycolytic Pathway and Cardiac Remodeling in Streptozotocin-Induced Diabetic Mice 
Volume 3, Issue 5, Pages (May 2001)
Development of a Rab9 Transgenic Mouse and Its Ability to Increase the Lifespan of a Murine Model of Niemann-Pick Type C Disease  Tatiana Kaptzan, Sally.
Volume 2, Issue 1, Pages (July 2000)
Volume 69, Issue 6, Pages (March 2006)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Volume 22, Issue 4, Pages (April 2014)
Elizabeth Morris, Alex Scibetta, Aiping Lu, Xueqin Gao, Johnny Huard
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
David J. Nikolic-Paterson, Shuang Wang, Hui Yao Lan 
Volume 11, Issue 1, Pages (January 2005)
Volume 16, Issue 3, Pages (March 2008)
Volume 17, Issue 5, Pages (May 2009)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Transgene Expression in the Brain Stem Effected by Intramuscular Injection of Polyethylenimine/DNA Complexes  Shu Wang, Nan Ma, Shujun J. Gao, Hanry Yu,
Volume 5, Issue 5, Pages (May 2002)
Volume 12, Issue 5, Pages (November 2005)
Molecular Therapy - Methods & Clinical Development
Volume 24, Issue 5, Pages (May 2016)
Volume 4, Issue 6, Pages (December 2001)
M.Brandon Parrott, Michael A. Barry  Molecular Therapy 
Use of Perfluorochemical Liquid Allows Earlier Detection of Gene Expression and Use of Less Vector in Normal Lung and Enhances Gene Expression in Acutely.
Volume 2, Issue 1, Pages (July 2000)
Volume 18, Issue 6, Pages (June 2010)
Volume 3, Issue 4, Pages (April 2001)
Volume 63, Issue 4, Pages (April 2003)
Volume 2, Issue 3, Pages (September 2000)
Volume 18, Issue 2, Pages (February 2010)
Volume 4, Issue 5, Pages (November 2001)
Volume 14, Issue 1, Pages (July 2011)
The African Origin of the Common Mutation in African American Patients with Glycogen- Storage Disease Type II  Jeffrey A. Becker, John Vlach, Nina Raben,
Volume 3, Issue 4, Pages (April 2001)
Characterization of the Dopamine Defect in Primary Cultures of Dopaminergic Neurons from Hypoxanthine Phosphoribosyltransferase Knockout Mice  Doug W.
Molecular Therapy - Nucleic Acids
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Receptor-Targeted Gene Delivery Using Multivalent Phagemid Particles
Volume 6, Issue 1, Pages (July 2002)
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
J.P O'Rourke, H Hiraragi, K Urban, M Patel, J.C Olsen, B.A Bunnell 
Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of niemann–pick.
68. Site Specific Intra-Placental Gene Transfer Corrects Fetal Growth Restriction in a Novel Mouse Model of Placental Insufficiency (PI)    Molecular.
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
Volume 12, Issue 5, Pages (November 2005)
Volume 123, Issue 6, Pages (December 2002)
Volume 4, Issue 1, Pages (July 2001)
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
Volume 18, Issue 4, Pages (April 2010)
Role of the amino-terminal domain of simian virus 40 early region in inducing tumors in secretin-expressing cells in transgenic mice  Christelle Ratineau,
Volume 3, Issue 3, Pages (March 2001)
Neonatal Ultraviolet Radiation Exposure Is Critical for Malignant Melanoma Induction in Pigmented Tpras Transgenic Mice  Elke Hacker, Nicole Irwin, H.
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Volume 17, Issue 6, Pages (June 2009)
Volume 3, Issue 6, Pages (June 2001)
Volume 18, Issue 6, Pages (June 2010)
Volume 18, Issue 6, Pages (June 2010)
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
Volume 9, Issue 3, Pages (March 2004)
Hepatocyte Growth Factor Regulates the miR-206-HDAC4 Cascade to Control Neurogenic Muscle Atrophy following Surgical Denervation in Mice  Wooshik Choi,
Volume 3, Issue 5, Pages (May 2001)
Molecular Therapy - Methods & Clinical Development
Volume 17, Issue 5, Pages (May 2009)
Long-Term and Therapeutic-Level Hepatic Gene Expression of Human Factor IX after Naked Plasmid Transfer in Vivo  Carol H. Miao, Arthur R. Thompson, Keith.
Zhijian Wu, Aravind Asokan, R. Jude Samulski  Molecular Therapy 
Volume 8, Issue 1, Pages (July 2003)
Volume 3, Issue 1, Pages 8-13 (January 2001)
Volume 2, Issue 3, Pages (September 2000)
Targeting expression of a transgene to the airway surface epithelium using a ciliated cell-specific promoter  Lawrence E Ostrowski, James R Hutchins,
Delivery of a Retroviral Vector Expressing Human β-Glucuronidase to the Liver and Spleen Decreases Lysosomal Storage in Mucopolysaccharidosis VII Mice 
Presentation transcript:

Volume 6, Issue 5, Pages 601-608 (November 2002) Glycogen Stored in Skeletal but Not in Cardiac Muscle in Acid α-Glucosidase Mutant (Pompe) Mice Is Highly Resistant to Transgene-Encoded Human Enzyme  Nina Raben, Tejas Jatkar, Alicia Lee, Nina Lu, Sunita Dwivedi, Kanneboyina Nagaraju, Paul H. Plotz  Molecular Therapy  Volume 6, Issue 5, Pages 601-608 (November 2002) DOI: 10.1006/mthe.2002.0716 Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 1 Immunodetection of GAA and GFP proteins using specific antibodies. Low levels of GAA protein (but not GFP protein) were detected in heart (H) and muscle (M) in F.3 single-transgenic GAA/Gaa–/– mice. The absence of GFP expression confirms that GAA is expressed at extremely low levels in GAA/Gaa–/– mice. Double-transgenic Mck-T-GAA/Gaa–/– mice derived from the F.3 line were used as positive controls (left lane). Note that the gel was loaded with 10 μg protein for Mck-T-GAA/Gaa–/– and 100 μg protein for GAA/Gaa–/–. Molecular Therapy 2002 6, 601-608DOI: (10.1006/mthe.2002.0716) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 2 PAS-stained section of cardiac muscle from 4- to 4.5-month-old mice. (A) Control Mck-T/Gaa–/– single-transgenic mutant mouse. (B, C, and D) Single-transgenic mutant mice (GAA/Gaa–/–; F.3) showing glycogen accumulation ranging from 0 to 0.5 to 1.6%, respectively. Original magnification, ×2.5. Molecular Therapy 2002 6, 601-608DOI: (10.1006/mthe.2002.0716) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 3 PAS-stained section of skeletal muscle from 4- to 4.5-month-old mice. (A) Control Mck-T/Gaa–/– single-transgenic mutant mouse. (B) Single-transgenic mutant mouse (GAA/Gaa–/–; F.3) showing glycogen accumulation similar to that in the control (3.3%). (C) Single-transgenic mutant mouse (GAA/Gaa–/–; F.3) showing reduced glycogen load (1.9%). Original magnification, ×10. Molecular Therapy 2002 6, 601-608DOI: (10.1006/mthe.2002.0716) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 4 PAS-stained section of cardiac muscle after somatic induction of GAA expression in Gca–/– mice. (A) Control Mck-T-GAA/Gaa–/– on dox for 3 months. (B and C) Induction in 2-month-old animals (2 months gene off/1 month on) resulting in near-complete glycogen clearance with the levels of GAA activity of 24 and 30% wild type, respectively. (D) Control Mck-T-GAA/Gaa–/– on dox for 9.5 months. (E and F) Induction in 6-month-old animals (6 months gene off/4 months on) resulting in only ≈ 50% glycogen reduction with the levels of GAA activity of 40 and 200% of wild type, respectively. Original magnification, ×2.5. Molecular Therapy 2002 6, 601-608DOI: (10.1006/mthe.2002.0716) Copyright © 2002 American Society for Gene Therapy Terms and Conditions

FIG. 5 PAS-stained section of skeletal muscle after somatic induction of GAA expression in 2-month-old Gaa–/– mice. (A) Control Mck-T-GAA/Gaa–/– on dox for 3 months; (B and C) 2 months gene off/1 month on, resulting in partial glycogen clearance with levels of GAA activity of 22 and 38% wild type, respectively. (D) Control Mck-T-GAA/Gaa–/– on dox for 5 months; (E and F) 2 months gene off/3 months on, resulting in ≈ 80% glycogen reduction even with the levels of GAA activity of ≈ 2 times (mouse 3-7) and 8 times (mouse 3-9) above normal, respectively. Original magnification, × 10. Molecular Therapy 2002 6, 601-608DOI: (10.1006/mthe.2002.0716) Copyright © 2002 American Society for Gene Therapy Terms and Conditions